Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0139

A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)

1:00PM-3:00PM: Abstract Number: 0142

A Systemic Autoinflammatory Syndrome Caused by NEMO Exon 5 Skipping

1:00PM-3:00PM: Abstract Number: 0128

Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015

1:00PM-3:00PM: Abstract Number: 0149

Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations

1:00PM-3:00PM: Abstract Number: 0125

Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab

1:00PM-3:00PM: Abstract Number: 0134

Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A

1:00PM-3:00PM: Abstract Number: 0140

Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON

1:00PM-3:00PM: Abstract Number: 0148

Dysferlin Associated Autoinflammatory Disease Causing Systemic Inflammation and Sterile Lung Abcesses Through Impaired Efferocytosis

1:00PM-3:00PM: Abstract Number: 0129

Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)

1:00PM-3:00PM: Abstract Number: 0124

Evaluation of Comorbidity Burden and Its Effect on Lung Disease Progression and Mortality in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features

1:00PM-3:00PM: Abstract Number: 0123

Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases

1:00PM-3:00PM: Abstract Number: 0146

Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0141

Is Rituximab Associated with Worse Outcomes in COVID-19 Patients? A Meta-analysis

1:00PM-3:00PM: Abstract Number: 0135

Janus Kinase Inhibitors in Severe and Refractory Inflammatory Ocular Pathology. Cases Reports and Literature Review

1:00PM-3:00PM: Abstract Number: 0143

National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol

1:00PM-3:00PM: Abstract Number: 0138

Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry

1:00PM-3:00PM: Abstract Number: 0132

Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre

1:00PM-3:00PM: Abstract Number: 0137

Polyarticular Arthritis and Osteolysis Caused by Mutations in the ASAH1 Gene: Farber Disease Clinical Presentations in the First-ever Natural History Study

1:00PM-3:00PM: Abstract Number: 0131

Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study

1:00PM-3:00PM: Abstract Number: 0133

Retention Rate of Targeted Therapies in Erdheim-Chester Disease

1:00PM-3:00PM: Abstract Number: 0147

Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study

1:00PM-3:00PM: Abstract Number: 0136

Sarcoidosis Incidence After mTOR Inhibitor Treatment

1:00PM-3:00PM: Abstract Number: 0126

Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?

1:00PM-3:00PM: Abstract Number: 0127

The Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study) Supports Multidimensional Disease Symptomatology with High Levels of Pain and Fatigue, and Low Levels of Function

1:00PM-3:00PM: Abstract Number: 0144

The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease

1:00PM-3:00PM: Abstract Number: 0130

Three Chinese Pedigrees of A20 Haploinsufficiency

1:00PM-3:00PM: Abstract Number: 0145

Vaccination Immune Response Against Sars-Cov-2 in Patients with Autoimmune Rheumatic Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].